SOPHiA GENETICS (NASDAQ:SOPH) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) saw strong trading volume on Thursday. Approximately 1,175,730 shares changed hands during trading, an increase of 275% from the previous session’s volume of 313,782 shares. The stock last traded at $7.27 and had previously closed at $7.06.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Trading Up 3.0%

The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market capitalization of $609.88 million, a price-to-earnings ratio of -6.33 and a beta of 0.95. The business’s 50-day simple moving average is $7.97 and its 200-day simple moving average is $6.22.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, research analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $326,598.36. Following the completion of the sale, the chairman owned 3,395,650 shares of the company’s stock, valued at approximately $27,606,634.50. The trade was a 1.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ross Muken sold 9,838 shares of SOPHiA GENETICS stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $79,982.94. Following the sale, the chief executive officer directly owned 660,391 shares of the company’s stock, valued at $5,368,978.83. This represents a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 300,043 shares of company stock worth $2,256,756 over the last ninety days. Company insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC boosted its position in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS in the first quarter valued at about $50,000. 1492 Capital Management LLC increased its holdings in SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.